Amendments to the Claims:

The following claims will replace all prior versions of the claims in this application (in the unlikely event that no claims follow herein, the previously pending claims will remain):

1. (Currently Amended) A compound represented by the following Formula 1:



[1]

wherein Z is



~~or~~



n, m, q and r independently represent integers from zero to 4 provided that n + m ≤ 4 and q + r ≤ 4; p and s independently represent integers from zero to 5 provided that p + s ≤ 5; ~~a, b, and c represent~~ a represents a double ~~bonds~~ bond which may be present or absent; when

present, the double ~~bonds~~ bond may be in the E or Z configuration and, when absent, the resulting ~~stereocenters~~ stereocenter may have the R- or S- configuration;

~~R and R' each independently represent a hydrogen atom; linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$; $-NH_2$; $-NHR'''$; -OH; $-OR'''$; $CONR_2''''$; a halogen atom; optionally substituted linear or branched C_1-C_{20} alkyl or optionally substituted linear or branched C_2-C_{20} alkenyl;~~

R'' independently represents a hydrogen atom; linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$, $-NH_2$, $-NHR'''$, $-NR_2'''$, -OH, $-OR'''$, a halogen atom; optionally substituted linear or branched C_1-C_{20} alkyl or optionally substituted linear or branched C_2-C_{20} alkenyl;

R''' independently represents linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-(CH_2)_x$-Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

~~R'''' independently represent a hydrogen atom; optionally substituted C_1-C_{20} alkyl; optionally substituted C_1-C_{20} alkoxy; optionally substituted C_2-C_{20} alkenyl; optionally substituted C_6-C_{10} aryl; or NR_2'''' represents a cyclic moiety;~~

Z' represents a hydrogen atom or a pharmaceutically acceptable counterion;

~~A, A' and A''~~ A and A' each independently represent a hydrogen atom; C_1-C_{20} acylamino; C_1-C_{20} acyloxy; C_1-C_{20} alkanoyl; C_1-C_{20} alkoxycarbonyl; C_1-C_{20} alkoxy; C_1-C_{20} alkylamino; C_1-C_{20} alkylcarboxylamino; carboxyl; cyano; halo; or hydroxy;

~~B, B' and B''~~ B and B' each independently represent C_2-C_{20} alkenoyl; aroyl, aralkanoyl; nitro; optionally substituted, linear or branched C_1-C_{20} alkyl; or optionally substituted linear or branched C_2-C_{20} alkenyl;

or A and B jointly, ~~A' and B' jointly, or A'' and B''~~ or A' and B' jointly independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR''', -O-, or -S-.

2. (Cancelled)

3. A pharmaceutical composition comprising:

a therapeutically effective amount of a compound represented by the following formula 1:



[1]

wherein Z is



~~or~~



n, m, q and r independently represent integers from zero to 4 provided that n + m ≤ 4 and q + r ≤ 4; p and s independently represent integers from zero to 5 provided that p + s ≤ 5; ~~a, b, and c represent~~ a represents a double ~~bonds~~ bond which may be present or absent; when present, the double ~~bonds~~ bond may be in the E or Z configuration and, when absent, the resulting ~~stereocenters~~ stereocenter may have the R- or S- configuration;

~~R and R' each independently represent a hydrogen atom; linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$; $-NH_2$; $-NHR'''$; -OH, $-OR'''$; $CONR_2''''$; a halogen atom; optionally substituted linear or branched C_1-C_{20} alkyl or optionally substituted linear or branched C_2-C_{20} alkenyl;~~

R'' independently represents a hydrogen atom; linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$, $-NH_2$, $-NHR'''$, $-NR_2'''$, -OH, $-OR'''$, a halogen atom; optionally substituted linear or branched C_1-C_{20} alkyl or optionally substituted linear or branched C_2-C_{20} alkenyl;

R''' independently represents linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-(CH_2)_x$-Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

~~R'''' independently represent a hydrogen atom; optionally substituted C_1-C_{20} alkyl; optionally substituted C_1-C_{20} alkoxy; optionally substituted C_2-C_{20} alkenyl; optionally substituted C_6-C_{10} aryl; or NR_2'''' represents a cyclic moiety;~~

Z' represents a hydrogen atom or a pharmaceutically acceptable counterion;

~~A, A' and A''~~ A and A' each independently represent a hydrogen atom; C_1-C_{20} acylamino; C_1-C_{20} acyloxy; C_1-C_{20} alkanoyl; C_1-C_{20} alkoxycarbonyl; C_1-C_{20} alkoxy; C_1-C_{20} alkylamino; C_1-C_{20} alkylcarboxylamino; carboxyl; cyano; halo; or hydroxy;

~~B, B' and B''~~ B and B' each independently represent C_2-C_{20} alkenoyl; aroyl, aralkanoyl; nitro; optionally substituted, linear or branched C_1-C_{20} alkyl; or optionally substituted linear or branched C_2-C_{20} alkenyl;

or A and B jointly~~, A' and B' jointly, or A'' and B''~~ or A' and B' jointly independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR''', -O-, or -S-;

in a physiologically acceptable carrier.

4. (Cancelled)

5. (Withdrawn and Currently Amended) A method of treating diabetes comprising:

administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:



[1]

wherein Z is



~~or~~



n, m, q and r independently represent integers from zero to 4 provided that n + m ≤ 4 and q + r ≤ 4; p and s independently represent integers from zero to 5 provided that p + s ≤ 5; ~~a, b, and c represent~~ a represents a double ~~bonds~~ bond which may be present or absent; when present, the double ~~bonds~~ bond may be in the E or Z configuration and, when absent, the resulting ~~stereocenters~~ stereocenter may have the R- or S- configuration;

~~R and R' each independently represent a hydrogen atom; linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$; $-NH_2$; $-NHR'''$; $-OH$; $-OR'''$; $-CONR_2'''$; a~~

~~halogen atom; optionally substituted linear or branched C_1-C_{20} alkyl or optionally substituted linear or branched C_2-C_{20} alkenyl;~~

R'' independently represents a hydrogen atom; linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$, $-NH_2$, $-NHR'''$, $-NR_2'''$, -OH, $-OR'''$, a halogen atom; optionally substituted linear or branched C_1-C_{20} alkyl or optionally substituted linear or branched C_2-C_{20} alkenyl;

R''' independently represents linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-(CH_2)_x$-Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

~~R'''' independently represent a hydrogen atom; optionally substituted C_1-C_{20} alkyl; optionally substituted C_1-C_{20} alkoxy; optionally substituted C_2-C_{20} alkenyl; optionally substituted C_6-C_{10} aryl; or NR_2'''' represents a cyclic moiety;~~

Z' represents a hydrogen atom or a pharmaceutically acceptable counterion;

~~A, A' and A''~~ A and A' each independently represent a hydrogen atom; C_1-C_{20} acylamino; C_1-C_{20} acyloxy; C_1-C_{20} alkanoyl; C_1-C_{20} alkoxycarbonyl; C_1-C_{20} alkoxy; C_1-C_{20} alkylamino; C_1-C_{20} alkylcarboxylamino; carboxyl; cyano; halo; or hydroxy;

~~B, B' and B''~~ B and B' each independently represent C_2-C_{20} alkenoyl; aroyl, aralkanoyl; nitro; optionally substituted, linear or branched C_1-C_{20} alkyl; or optionally substituted linear or branched C_2-C_{20} alkenyl;

or A and B jointly~~, A' and B' jointly, or A'' and B''~~ or A' and B' jointly independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR''', -O-, or -S-;

in a physiologically acceptable carrier.

6. (Cancelled).

7. (Withdrawn and Currently Amended) A method of treating inflammation or inflammatory disease comprising:

administering to a subject suffering from such condition, a therapeutically effective amount of a compound represented by the following formula 1:



[1]

wherein Z is



~~or~~



n, m, q and r independently represent integers from zero to 4 provided that n + m ≤ 4 and q + r ≤ 4; p and s independently represent integers from zero to 5 provided that p + s ≤ 5; ~~a, b, and c represent~~ a represents a double ~~bonds~~ bond which may be present or absent; when present, the double ~~bonds~~ bond may be in the E or Z configuration and, when absent, the resulting ~~stereocenters~~ stereocenter may have the R- or S- configuration;

~~R and R' each independently represent a hydrogen atom; linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$; $-NH_2$; $-NHR'''$; $-OH$; $-OR'''$; $-CONR_2''''$; a~~

~~halogen atom; optionally substituted linear or branched C_1-C_{20} alkyl or optionally substituted linear or branched C_2-C_{20} alkenyl;~~

R'' independently represents a hydrogen atom; linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; -CO_2Z'; -CO_2R''', -NH_2, -NHR''', -NR_2''', -OH, -OR''', a halogen atom; optionally substituted linear or branched C_1-C_{20} alkyl or optionally substituted linear or branched C_2-C_{20} alkenyl;

R''' independently represents linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; –$(CH_2)_x$-Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

~~R'''' independently represent a hydrogen atom; optionally substituted C_1-C_{20} alkyl; optionally substituted C_1-C_{20} alkoxy; optionally substituted C_2-C_{20} alkenyl; optionally substituted C_6-C_{10} aryl; or NR_2'''' represents a cyclic moiety;~~

Z' represents a hydrogen atom or a pharmaceutically acceptable counterion;

~~A, A' and A''~~ A and A' each independently represent a hydrogen atom; C_1-C_{20} acylamino; C_1-C_{20} acyloxy; C_1-C_{20} alkanoyl; C_1-C_{20} alkoxycarbonyl; C_1-C_{20} alkoxy; C_1-C_{20} alkylamino; C_1-C_{20} alkylcarboxylamino; carboxyl; cyano; halo; or hydroxy;

~~B, B' and B''~~ B and B' each independently represent C_2-C_{20} alkenoyl; aroyl, aralkanoyl; nitro; optionally substituted, linear or branched C_1-C_{20} alkyl; or optionally substituted linear or branched C_2-C_{20} alkenyl;

or A and B jointly~~, A' and B' jointly, or A'' and B''~~ or A' and B' jointly independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR''', -O-, or -S-;

in a physiologically acceptable carrier.

8. (Cancelled).

9. (Withdrawn and Currently Amended) A method of treating immunological disease comprising:

administering to a subject suffering from an immunological disease, a therapeutically effective amount of a compound represented by the following formula 1:



[1]

wherein Z is



~~or~~



n, m, q and r independently represent integers from zero to 4 provided that n + m ≤ 4 and q + r ≤ 4; p and s independently represent integers from zero to 5 provided that p + s ≤ 5; ~~a, b, and c represent~~ a represents a double ~~bonds~~ bond which may be present or absent; when present, the double ~~bonds~~ bond may be in the E or Z configuration and, when absent, the resulting ~~stereocenters~~ stereocenter may have the R- or S- configuration;

~~R and R' each independently represent a hydrogen atom; linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; $-CO_2Z'$; $-CO_2R'''$; $-NH_2$; $-NHR'''$; $-OH$; $-OR'''$; $CONR_2''''$; a~~

~~halogen atom; optionally substituted linear or branched C_1-C_{20} alkyl or optionally substituted linear or branched C_2-C_{20} alkenyl;~~

R" independently represents a hydrogen atom; linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; -CO_2Z'; -CO_2R''', -NH_2, -NHR''', -NR_2''', -OH, -OR''', a halogen atom; optionally substituted linear or branched C_1-C_{20} alkyl or optionally substituted linear or branched C_2-C_{20} alkenyl;

R''' independently represents linear or branched C_1-C_{20} alkyl; linear or branched C_2-C_{20} alkenyl; –$(CH_2)_x$-Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

~~R'''' independently represent a hydrogen atom; optionally substituted C_1-C_{20} alkyl; optionally substituted C_1-C_{20} alkoxy; optionally substituted C_2-C_{20} alkenyl; optionally substituted C_6-C_{10} aryl; or NR_2'''' represents a cyclic moiety;~~

Z' represents a hydrogen atom or a pharmaceutically acceptable counterion;

~~A, A' and A"~~ A and A' each independently represent a hydrogen atom; C_1-C_{20} acylamino; C_1-C_{20} acyloxy; C_1-C_{20} alkanoyl; C_1-C_{20} alkoxycarbonyl; C_1-C_{20} alkoxy; C_1-C_{20} alkylamino; C_1-C_{20} alkylcarboxylamino; carboxyl; cyano; halo; or hydroxy;

~~B, B' and B"~~ B and B' each independently represent C_2-C_{20} alkenoyl; aroyl, aralkanoyl; nitro; optionally substituted, linear or branched C_1-C_{20} alkyl; or optionally substituted linear or branched C_2-C_{20} alkenyl;

or A and B jointly~~, A' and B' jointly, or A" and B"~~ or A' and B' jointly independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR''', -O-, or -S-;

in a physiologically acceptable carrier.

10. (Cancelled)

11. (Withdrawn and Currently Amended) A method of inhibiting the activity of TNF-alpha, IL-1, IL-6 or COX-2 which comprises administering to a host in need of such inhibition an effective amount of a compound according to claim 1 ~~or claim 2~~.

12. (Withdrawn and Currently Amended) The method of inhibiting the undesired action of ~~cytokine~~ cytokines or cyclooxygenase which comprises administering to a host in need of such inhibition an effective amount of a compound according to claim 1 ~~or claim 2~~.

13. (Withdrawn and Currently Amended) The method of treating a disease mediated by cytokines or cyclooxygenase which comprises administering to a host in need of such treatment a compound according to claim 1 ~~or claim 2~~.

14. (Withdrawn and Currently Amended) The method of treating insulin resistance which comprises administering to a host in need of such treatment an effective amount of a compound according to claim 1 ~~or claim 2~~.

15. (Withdrawn and Currently Amended) The method of treating hyperlipidemia which comprises administering to a host in need of such treatment an effective amount of a compound according to claim 1 ~~or claim 2~~.

16. (Withdrawn and Currently Amended) The method of treating coronary heart disease which comprises administering to a host in need of such treatment an effective amount of a compound according to claim 1 ~~or claim 2~~.

17. (Withdrawn and Currently Amended) The method of treating multiple sclerosis which comprises administering to a host in need of such treatment an effective amount of a compound according to claim 1 ~~or claim 2~~.

18. (Withdrawn and Currently Amended) The method of treating cancer which comprises administering to a host in need of such treatment an effective amount of a compound according to claim 1 ~~or claim 2~~.

19. (Currently Amended) A compound according to claim 1 selected from the group consisting of:

~~2-{4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenoxy]-phenyl}-3-p-tolylacrylic acid,~~

~~2-{4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl}-3-p-tolylacrylic acid,~~

~~2-[4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl]-3-p-tolylacrylic acid methyl ester,~~

~~3-(3,5-dimethylphenyl)-2-[4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenoxy]-phenyl]-acrylic acid,~~

~~3-(3,5-dimethylphenyl)-2-[4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl]-acrylic acid,~~

~~3-(3,5-dimethylphenyl)-2-[4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl]-acrylic acid methyl ester,~~

~~5-(4-[4-[2-(3,5-dimethylphenyl)-1-(morpholine-4-carbonyl)-vinyl]-phenoxy}-benzyl)-thiazolidine-2,4-dione,~~

~~5-(4-[4-[2-(4-methoxyphenyl)-vinyl]-phenoxy}-benzyl)-thiazolidine-2,4-dione,~~

~~5-(4-[4-[2-(3,5-dimethylphenyl)-vinyl]-phenoxy}-benzyl)-thiazolidine-2,4-dione,~~

5-[4-(4'-methoxybiphenyl-3-yloxy)-benzylidene]-thiazolidine-2,4-dione,

5-[4-(4'-methoxybiphenyl-3-yloxy)-benzyl]-thiazolidine-2,4-dione,

5-[4-(2',4'-dimethoxybiphenyl-3-yloxy)-benzylidene]-thiazolidine-2,4-dione, and

~~5-[4-(3',5'-dimethoxybiphenyl-3-yloxy)-benzyl]-thiazolidine-2,4-dione~~

5-[4-(2',4'-dimethoxybiphenyl-3-yloxy)-benzyl]-thiazolidine-2,4-dione.

20. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of:

~~2-[4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenoxy]-phenyl]-3-p-tolylacrylic acid,~~

~~2-[4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl]-3-p-tolylacrylic acid,~~

~~2-[4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl]-3-p-tolylacrylic acid methyl ester,~~

~~3-(3,5-dimethylphenyl)-2-[4-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenoxy]-phenyl]-acrylic acid,~~

~~3-(3,5-dimethylphenyl)-2-[4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl]-acrylic acid,~~

~~3-(3,5-dimethylphenyl)-2-[4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl]-acrylic acid methyl ester,~~

~~5-(4-[4-[2-(3,5-dimethylphenyl)-1-(morpholine-4-carbonyl)-vinyl]-phenoxy}-benzyl)-thiazolidine-2,4-dione,~~

~~5-(4-[4-[2-(4-methoxyphenyl)-vinyl]-phenoxy}-benzyl)-thiazolidine-2,4-dione,~~

~~5-(4-[4-[2-(3,5-dimethylphenyl)-vinyl]-phenoxy}-benzyl)-thiazolidine-2,4-dione,~~

5-[4-(4'-methoxybiphenyl-3-yloxy)-benzylidene]-thiazolidine-2,4-dione;

5-[4-(4'-methoxybiphenyl-3-yloxy)-benzyl]-thiazolidine-2,4-dione;

5-[4-(2',4'-dimethoxybiphenyl-3-yloxy)-benzylidene]-thiazolidine-2,4-dione; and

~~5-[4-(3',5'-dimethoxybiphenyl-3-yloxy)-benzyl]-thiazolidine-2,4-dione~~

5-[4-(2',4'-Dimethoxybiphenyl-3-yloxy)-benzyl]-thiazolidine-2,4-dione,

together with a physiologically acceptable carrier therefore.

21. (Withdrawn and Currently Amended) A method for treating diabetes comprising: co-administering an effective amount of a compound of claim 1 ~~or claim 2~~ and an agent selected from the group consisting of:

insulin or an insulin mimetic,
a sulfonylurea or other insulin secretagogue,
a thiazolidinedione,
a fibrate or other PPAR-alpha agonist,
a PPAR-delta agonist,
a biguanide,
a statin or other hydroxymethylglutaryl (HMG) CoA reductase inhibitor,
an alpha-glucosidase inhibitor,
a bile-acid binding resin,
apoA1,
niacin,
probucol,
and nicotinic acid.

22. (Withdrawn and Currently Amended) A method for treating inflammatory or immunological disease, comprising: co-administering an effective amount of a compound of claim 1 ~~or claim 2~~ and an agent selected from the group consisting of:

a non-steroidal anti-inflammatory drug (NSAID),
a cyclooxygenase-2 inhibitor,
a corticosteroid or other immunosuppressive agent,
a disease-modifying antirheumatic drug (DMARD),
a TNF-alpha inhibitor,
other cytokine inhibitor,
other immune modulating agent,
and a narcotic agent.

23-24. (Cancelled)

25. (New) A compound according to claim 1, wherein X represents -S-; and X' represents >NH.

26. (New) A compound according to claim 25, wherein A independently is C_1-C_{20} alkoxy and p is 1 or 2.

27. (New) A compound according to claim 26, wherein m, n, q, r and s are zero.

28. (New) A compound according to claim 27, wherein the bond identified by a is a single bond.

29. (New) A compound according to claim 28, wherein R" represents a hydrogen atom.